Nazara Technologies has announced the approval for granting 5,66,463 employee stock options under its ‘ESOP 2025’ scheme. This decision was formalized via circulation on March 02, 2026. The exercise price for these options has been set at ₹264.80 per share. The options are granted to eligible employees and will vest according to specified conditions, with a minimum one-year period between grant and vesting.
Employee Stock Option Grant Approved
Nazara Technologies Limited has formally intimated the grant of employee stock options under the “Nazara Technologies Employee Stock Option Scheme 2025” (“ESOP 2025”). The approval for this grant was passed by the Nomination, Remuneration and Compensation Committee of the Board of Directors via a resolution circulated on Monday, March 02, 2026.
Key Figures of the Grant
- Total number of options granted: 5,66,463 (Five Lakhs Sixty-Six Thousand Four Hundred and Sixty-Three).
- Total shares covered: Equivalent to 5,66,463 Equity Shares of Face Value of ₹2.00 each.
Pricing and Vesting Details
The exercise price for these stock options has been determined at ₹264.80 (Rupees Two Hundred Sixty-Four and Eighty Paise Only) per option. This price corresponds to the closing price of the Company’s shares on the National Stock Exchange of India Limited on February 27, 2026.
The significant terms governing these options include:
- The options will vest within the specified vesting period according to the grant letter and ESOP 2025 terms.
- A minimum period of one (1) year must elapse between the grant date and the vesting date.
- The options can be exercised anytime after vesting and within 5 (Five) years from the vesting date, as per ESOP 2025 terms.
- There is no lock-in on the equity shares issued upon exercise.
- Any resulting equity shares will rank pari-passu with all other existing equity shares from the date of allotment.
Compliance Confirmation
The grant confirms compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The Company confirmed that no options have yet been exercised or lapsed, and no variations to the terms have occurred. The item was executed by Arun Bhandari, Company Secretary and Compliance Officer.
Source: BSE
